Iguana Healthcare Management LLC increased its holdings in TESARO Inc (NASDAQ:TSRO) by 66.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,000 shares of the biopharmaceutical company’s stock after purchasing an additional 10,000 shares during the period. TESARO accounts for 1.7% of Iguana Healthcare Management LLC’s holdings, making the stock its 24th biggest holding. Iguana Healthcare Management LLC’s holdings in TESARO were worth $3,228,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Neuberger Berman Group LLC raised its holdings in shares of TESARO by 22.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 153,540 shares of the biopharmaceutical company’s stock worth $19,822,000 after acquiring an additional 28,500 shares in the last quarter. Bamco Inc. NY raised its holdings in shares of TESARO by 30.7% during the 3rd quarter. Bamco Inc. NY now owns 13,128 shares of the biopharmaceutical company’s stock worth $1,695,000 after acquiring an additional 3,087 shares in the last quarter. Perceptive Advisors LLC raised its holdings in shares of TESARO by 8.1% during the 3rd quarter. Perceptive Advisors LLC now owns 388,651 shares of the biopharmaceutical company’s stock worth $50,175,000 after acquiring an additional 29,100 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of TESARO by 24.9% during the 3rd quarter. Janus Henderson Group PLC now owns 895,556 shares of the biopharmaceutical company’s stock worth $115,616,000 after acquiring an additional 178,406 shares in the last quarter. Finally, Vident Investment Advisory LLC raised its holdings in shares of TESARO by 379.4% during the 3rd quarter. Vident Investment Advisory LLC now owns 5,652 shares of the biopharmaceutical company’s stock worth $729,000 after acquiring an additional 4,473 shares in the last quarter.

In other news, SVP Martin H. Jr. Huber sold 592 shares of the stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $118.60, for a total transaction of $70,211.20. Following the transaction, the senior vice president now owns 6,943 shares of the company’s stock, valued at approximately $823,439.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the transaction, the senior vice president now directly owns 8,101 shares in the company, valued at approximately $690,529.24. The disclosure for this sale can be found here. Insiders have sold a total of 11,421 shares of company stock worth $1,312,175 in the last three months. Corporate insiders own 34.60% of the company’s stock.

TESARO Inc (NASDAQ TSRO) opened at $83.03 on Thursday. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34. TESARO Inc has a 12-month low of $79.03 and a 12-month high of $192.94.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. The company had revenue of $142.77 million for the quarter, compared to the consensus estimate of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. TESARO’s quarterly revenue was up 740.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.72) EPS. research analysts predict that TESARO Inc will post -8.17 EPS for the current year.

Several brokerages have recently issued reports on TSRO. Credit Suisse Group set a $190.00 price objective on TESARO and gave the stock a “buy” rating in a report on Friday, August 18th. HC Wainwright reaffirmed a “buy” rating and set a $158.00 price objective on shares of TESARO in a report on Monday, November 20th. Evercore ISI began coverage on TESARO in a report on Wednesday, August 16th. They set an “in-line” rating and a $121.00 price objective on the stock. SunTrust Banks reaffirmed a “buy” rating and set a $160.00 price objective on shares of TESARO in a report on Friday, November 10th. Finally, Piper Jaffray Companies reissued a “neutral” rating and set a $117.00 target price on shares of TESARO in a research report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $159.39.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/12/14/tesaro-inc-tsro-shares-bought-by-iguana-healthcare-management-llc.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related stocks with our FREE daily email newsletter.